You are here: Industry Insights > Diabetes

News List

Novo Nordisk’s diabetes pill presents the first successful data biospectrumasia
February 27, 2018
The oral form of the drug, known generically as semaglutide, is crucial for ensuring the group's long-term growth, as price pressure mounts in a crowded market targeting the world's 450 million diabetics.
Semaglutide Demonstrated Significant Reductions in Blood Sugar and Weight Compared with Dulaglutide; prnasia
February 02, 2018
The Lancet Diabetes and Endocrinology has published the results of the SUSTAIN 7 trial
New Player Joining, what will be Its Odds of Success in Marching into the Hypoglycemic Drug Market? Xiaoyaowan
January 23, 2018
New Player Joining the Chinese Class 1 New Drugs of DPP-4 Inhibitor Type, what will be Its Odds of Success in Marching into the Hypoglycemic Drug Market?
Creative Peptides Added New GLP-1 Peptides for Diabetes Research biospace
January 16, 2018
On January 11, 2018, the leading peptide expert Creative Peptides announced to add new GLP-1 peptides targeting for diabetes research.
Interactive app provides disease management tool for diabetes europeanpharmaceuticalreview
January 12, 2018
Scientists have developed an online interactive app to help motivate patients to be more active in managing their disease…
USPTO Grants Glytec Patent Allowance for Computer-Guided Selection and Dosing of All Diabetes Medica biospace
January 10, 2018
As a market leader in insulin-managed enterprise software solutions, Glytec is extending its intellectual property protection and providing new patent subsidies to solve all diabetes drug optimization issues
Drug for diabetes type 2 shows potential in treating Alzheimer’s biospectrumasia
January 05, 2018
The drug could also enhance levels of a brain growth factor which protects nerve cell functioning, and slows down the rate of nerve cell loss, among other benefits.
FDA Approves Marketing of Sanuwave's Shock Wave Device for Diabetic Foot Ulcers biospace
January 02, 2018
Today, the U.S. Food and Drug Administration (FDA) permitted the marketing of the Dermapace System, the first shock wave device intended to treat diabetic foot ulcers.
FDA Approves New Type 2 Diabetes Drug From Merck, Pfizer biospace
December 22, 2017
The U.S. Food and Drug Administration approved Merck’s and Pfizer’s Steglatro (ertugliflozin), a sodium-glucose co-transporter 2 (SGLT2)- inhibitor, that will square off against established drugs in the market.
Xultophy® shows significant results for type 2 diabetes patients in real-world setting pharmaasia
December 19, 2017
Xultophy® by Novo Nordisk has been shown to significantly reduced blood sugar levels in people with type 2 diabetes after six months.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 38 39 Next page